Shurgard Self Storage, a leading European self-storage REIT, is currently trading at a significant discount to its net tangible assets (NTA) with a valuation of 0.48x NTA. It offers an attractive dividend yield of 4.5% and benefits from strong urbanization-driven demand and high occupancy rates of 85%. However, recent revenue and net operating income growth have slowed due to competitive pricing pressures, leading the company to reduce its 2026 guidance and withdraw medium-term targets. Despite these short-term challenges, Shurgard's solid financial position with a low loan-to-value ratio of 23.7% and its defensive business profile make it a compelling value and income investment opportunity.
Shurgard Self Storage is the subject, with Pluang's Real Estate sector data as context. As of Nov 12, 2026 03:21 WIB, among 47 priced Real Estate-sector US stocks tradable on Pluang, 14 rose and 33 fell. Notable movers include Alexandria Real Estate Equities Inc (ARE) at USD 45.37 with a 1-day change of +1.50% and 100% buy order activity, Iron Mountain Inc (IRM) at USD 112.42 with a 1-day change of +1.48%, and Orion Office REIT Inc (ONL) at USD 2.67 with a 1-day change of -1.48% and 100% sell order activity. The most notable figure is ARE's 100% buy order activity.
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Kiniksa Pharmaceuticals International, plc announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026. The event will be webcast live and available for replay on the ...
Lakefront Biotherapeutics reported a net profit of €13.9 million for the first nine months of 2026, a significant turnaround from a €461.3 million loss in the same period last year. The company highlighted progress with its autoimmune drug gamgertami...
OptimizeRx reported Q3 2026 revenue of $21.6 million, down 17% year-over-year, but net income rose to $1.2 million. Adjusted EBITDA increased 23% to $6.3 million, reflecting improved margins and cost management. The company updated its 2026 revenue g...
